After six years of independent research, Sánchez-Serrano concluded that the biggest obstacle is not a lack of medical insurance but a lack of access to effective and appropriate medicines.
Waltham, MA (PRWEB) November 15, 2011
Finding effective ways to provide and pay for health care, in particular for medicines, is no longer a problem exclusive to the less developed countries but is also a growing challenge in the world’s richest countries. In his new book The World's Health Care Crisis: From the Laboratory Bench to the Patient’s Bedside (Elsevier, 2011), Panamanian researcher Ibis Sánchez-Serrano provides concrete solutions that will improve access to affordable medicines throughout the world.
After six years of independent research, Sánchez-Serrano concluded that the biggest obstacle is not a lack of medical insurance but a lack of access to effective and appropriate medicines. Lack of access to medications is the common denominator in all the nations of the world, regardless of whether their health care systems are public or private. His book focuses on the role played by the bio-pharmaceutical industry in the global health crisis.
Sánchez-Serrano points out that "health care reform must begin with reform in the way in which medicines are created and, therefore, priced, which requires a series of improvements at the pharmaceutical research and development (R&D) level ."
His research is based on the analysis of thousands of documented sources and dozens of interviews with world leaders in health care, the bio-pharmaceutical industry, investors, regulators, bankers, scientists, academics, and philanthropists in the United States and the European Union.
Sanchez-Serrano’s book grew out of a research article published in the highly regarded Nature Reviews Drug Discovery. That article described the development, in record time and without the usual cost for the pharmaceutical industry, of the anti-cancer drug Velcade (Proscript / Millennium Pharmaceuticals).
Generous support from a Swiss patron, not related to the pharmaceutical industry or politics, allowed Sánchez-Serrano to investigate, in depth and objectively, the health care systems of the United States, Europe, Asia, Latin America, Africa, Canada and Australia, as well as biotechnology and pharmaceutical industries.
Ibis Sánchez- Serrano was born in the city of Santiago de Veraguas, Panama, and trained in some of the world’s leading academic centers, including Tufts, Harvard, and the Sloan School of Management of the Massachusetts Institute of Technology, among others. Sánchez-Serrano will soon begin a series of lectures and conferences around the world presenting the results of his research. For more information visit: ibissanchezserrano.com.
About Elsevier Science & Technology Books
Elsevier Science & Technology Books provides its superior content through its books and online resources such as SciVerse ScienceDirect books and BrainNavigator, the award-winning product that improves the quality of neuroscience research. The S&T Books’ family of imprints includes leaders in the media technology market with Focal Press and computing market with Morgan Kaufmann. Other imprints include Newnes, Syngress, William Andrew, CIMA, Butterworth-Heinemann, Academic Cell, Anderson Press, and Gulf Publishing (http://www.ElsevierDirect.com/). For students and instructors, we offer high-quality textbooks. Browse our offerings at textbooks.elsevier.com.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV.
# # #